Country: Canada
Language: English
Source: Health Canada
GLATIRAMER ACETATE
TEVA CANADA LIMITED
L03AX13
GLATIRAMER ACETATE
20MG
SOLUTION
GLATIRAMER ACETATE 20MG
SUBCUTANEOUS
30
Prescription
Immunomodulatory Agents
Active ingredient group (AIG) number: 0132525001; AHFS:
APPROVED
2015-06-19
_Page 1 of 36_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-GLATIRAMER ACETATE glatiramer acetate injection 20 mg / mL and 40 mg / mL Single-Use Pre-filled syringes for Subcutaneous Injection Immunomodulator Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 www.tevacanada.com CONTROL NUMBER: 254069 Date of Revision: December 10, 2021 _Page 2 of 36_ RECENT MAJOR LABEL CHANGES 6 Warnings and Precautions 12/2021 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.............................................................. 3 1 INDICATIONS ................................................................................................................. 3 1.1 Pediatrics ............................................................................................................. 3 1.2 Geriatrics.............................................................................................................. 3 2 CONTRAINDICATIONS ................................................................................................... 3 3 DOSAGE AND ADMINISTRATION .................................................................................. 3 3.1 Dosing Considerations .......................................................................................... 3 3.2 Recommended Dose and Dosage Adjustment ...................................................... 4 3.3 Administration....................................................................................................... 4 3.4 Missed Dose......................................................................................................... 4 4 OVERDOSAGE ............................................................................................................... 4 5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............................ 5 6 WARNINGS AND PRECAUTIONS................................................................................... 5 6.1 Special Populations ...................................... Read the complete document